Document resource
Background/Objectives Previously reported data up to 6 years of ofatumumab treatment demonstrated a favourable safety profile and sustained efficacy. Here we describe long-term safety of ofatumumab and assess disability outcomes (up to 7 years) of early initiation of ofatumumab treatment versus delayed treatment (after switching from teriflunomide) in people with relapsing multiple sclerosis (pwRMS).Methods Safety analyses include participants who received ≥1 dose of ofatumumab in ASCLEPIOS I/II, APOLITOS, APLIOS, or ALITHIOS. Efficacy analyses evaluate cumulative data up to 7 years (cutoff: 25-Sep-2024) from pwRMS randomized to ofatumumab or teriflunomide in ASCLEPIOS I/II, regardless of whether they entered the ALITHIOS open-label extension phase. Event rates of 3/6-month (m) confirmed disability worsening (3/6mCDW), progression independent of relapse activity (3/6mPIRA; CDW events without prior confirmed relapses), and relapse-associated disability worsening (3/6mRAW; disability onset <90 days from relapse) will be assessed.Results Exposure-adjusted incidence rates of adverse events (AEs), serious AEs, serious infections, and malignancies remained low and consistent, with no increased risk over 6 years. Previously reported 6-year data (cutoff: 25-Sep-2023) showed Kaplan-Meier cumulative event rates were numerically lower in pwRMS receiving continuous ofatumumab in ASCLEPIOS I/II and ALITHIOS (OMB-OMB) versus delayed treatment (TER-OMB) for 6mCDW (21.1% vs 24.8%, p=0.063), 6mPIRA (15.5% vs 16.6%), and 6mRAW (5.2% vs 5.8%). Updated 7-year safety and efficacy data will be presented at the congress.Conclusion These analyses will further support long-term safety and efficacy data for ofatumumab in pwRMS, including RDTN pwRMS, informing clinical decision-making.